Comparative Pharmacology
Head-to-head clinical analysis: GLIADEL versus MELPHALAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLIADEL versus MELPHALAN HYDROCHLORIDE.
GLIADEL vs MELPHALAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLIADEL (carmustine implant) is a biodegradable wafer that delivers carmustine, a nitrosourea alkylating agent, directly into the tumor resection cavity. Carmustine alkylates DNA and RNA, leading to cross-linking and inhibition of DNA replication, ultimately causing cell death. It is cell cycle phase nonspecific.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
Gliadel (carmustine) implant is administered intraoperatively as 8 wafers, each containing 7.7 mg carmustine, placed in the resection cavity after tumor debulking. Maximum dose is 61.6 mg (8 wafers).
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
None Documented
None Documented
Terminal elimination half-life is approximately 1.3 hours for the active dianhydrogalactitol metabolite. Clinical context: short half-life supports local interstitial delivery with minimal systemic accumulation.
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Primarily renal (60-70% as unchanged drug and metabolites) and biliary/fecal (15-20%). Approximately 10-15% is eliminated via exhaled air as CO2.
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Category C
Category D/X
Alkylating Agent
Alkylating Agent